The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.50
Bid: 4.34
Ask: 4.80
Change: 1.03 (29.68%)
Spread: 0.46 (10.599%)
Open: 3.64
High: 4.50
Low: 3.64
Prev. Close: 3.47
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wilbur Ellis Agreement

14 Jun 2023 07:00

RNS Number : 6732C
Plant Health Care PLC
14 June 2023
 

14 June 2023

 

Plant Health Care plc

 ("Plant Health Care" or the "Company")

 

Plant Health Care® ("PHC") and Wilbur-Ellis® Agribusiness Announce Distribution Agreement to Support First OBRONATM Commercial Sales in the U.S.

 

Plant Health Care® (AIM.PHC.L), a leading provider of peptides for plant protection to global agriculture markets, is pleased to announce it has concluded a distribution agreement ("The Agreement") with Wilbur-Ellis® Agribusiness, one of the largest U.S. retailers of agricultural products. The Agreement will support commercial sales of OBRONATM, a foliar fungicide recently approved by US EPA which is expected to be available within key US markets during the summer of 2023. Obrona is a unique product developed to help growers control a wide range of fungal and bacterial plant pathogens within fruits, nuts, vegetables, and row crops.

 

Plant Health Care and Wilbur-Ellis have been working together in an exclusive partnership since 2020 to evaluate and develop PHC279, the active ingredient in OBRONA, for high value specialty and row crop markets. Multiple years of field trials have validated product efficacy to support initial launch focused on corn diseases, such as tar spot (Phyllachora maydis), Gray leaf spot (Cercospora zeae-maydis), and common rust (Puccinia sorghi), as well as powdery and downy mildew and various other diseases in grapes, as well as white mold (Sclerotinia sclerotiorum) and other diseases affecting leafy vegetables within key Western US states.

 

Derived from naturally occurring proteins, PHC279 is the first product from the Company's PREtec technology platform (Vaccines for Plants™) that will be available to US farmers. PREtec stimulates crop growth and enhances crop resistance to fungal and bacterial diseases and improves crop quality and yield. The Company's initial PREtec product, Saori® is successfully being used in Brazil as a seed treatment to control an array of soybean diseases including Asian Soybean Rust (Phakopsora spp.).

 

PREtec provides growers with a novel and environmentally friendly approach to growing crops and is compatible with mainstream agricultural practices. As part of an integrated pest management program, OBRONA will reduce reliance on older synthetic pesticides and will provide growers with a valuable tool to proactively manage disease resistance. The availability of OBRONA will support farmers seeking to use more sustainable and environmentally friendly practices while continuing to provide safe, abundant, and high-quality food.

 

Plant Health Care continues to expand into new markets around the world through strategic partnerships with major global distribution partners. The Company is on track to achieve revenue of $30 million by 2025, through the launch of new products and continued growth through current and future distributor relationships, and to achieve cash breakeven and profit along that track.

 

Jeff Tweedy, CEO of Plant Health Care, said: ‟Having worked with Wilbur-Ellis on the development of OBRONA for more than three years, I am gratified that this new agreement will bring OBRONA to the market to enable control of many of the most recalcitrant fungal and bacterial pathogens challenging growers today. OBRONA will support sustainable agriculture with better crops delivering higher yield for thousands of U.S. farmers."

 

 

Scott Addy, Wilbur-Ellis Agribusiness VP Branded Technologies and Biological Solutions, said: "We are pleased that our partnership with Plant Health Care has resulted in the approval of OBRONA and are looking forward to launching the product this summer to deliver value to the grower in a sustainable way. We expect that there will be many other products that follow, and we will continue to offer our growers biological options to solve their pest issues."

 

 

# # #

 

 

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes, and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile.

 

Find out more at www.planthealthcare.com

 

About the Wilbur-Ellis Companies 

 

Founded in 1921, the Wilbur-Ellis companies are leading marketers, distributors and manufacturers of agricultural products and animal nutrients. By developing strong relationships, making strategic market investments, and capitalizing on new opportunities, the Wilbur-Ellis companies have continued to grow the business with sales of over $3.5 billion. For more information, please visit www.wilburellis.com

 

For further information, please contact: 

Plant Health Care plc Jeff Tweedy, CEO

Tel: +1 919 926 1600

Cenkos Securities plc - Nomad & Broker Neil McDonald / Pete Lynch

Tel: +44 (0) 131 220 9771

SEC Newgate (Financial Communications) Robin Tozer / George Esmond / Harry Handyside

Tel: +44 (0)7540 106 366 Email: phc@secnewgate.co.uk

For further information about Wilbur-Ellis, please contact:

Jeanne Forbis, email:jforbis@wilburellis.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEASKLFDLDEEA
Date   Source Headline
18th Aug 20214:41 pmRNSSecond Price Monitoring Extn
18th Aug 20214:36 pmRNSPrice Monitoring Extension
9th Aug 20211:27 pmRNSHolding(s) in Company
3rd Aug 20217:00 amRNSAdmission to the U.S. OTCQB Venture Market
27th Jul 20217:00 amRNSNew Distribution Agreement with Agrii UK
26th Jul 20217:00 amRNS2021 Half-Year Trading Statement
23rd Jul 20217:00 amRNSGrant of Options
22nd Jul 20217:00 amRNSInvestor Presentation
12th Jul 20214:40 pmRNSSecond Price Monitoring Extn
12th Jul 20214:35 pmRNSPrice Monitoring Extension
29th Jun 20214:41 pmRNSSecond Price Monitoring Extn
29th Jun 20214:35 pmRNSPrice Monitoring Extension
14th Jun 20212:33 pmRNSResult of AGM
14th Jun 20217:00 amRNSGreen Economy Mark awarded
9th Jun 20214:41 pmRNSSecond Price Monitoring Extn
9th Jun 20214:35 pmRNSPrice Monitoring Extension
20th May 20217:00 amRNSInvestor Presentation
7th May 20213:50 pmRNSAnnual Report & Accounts and AGM Notice Published
30th Apr 20215:40 pmRNSHolding(s) in Company
23rd Apr 20217:00 amRNSResults for the year ended 31 December 2020
21st Apr 202111:58 amRNSHolding(s) in Company
8th Apr 20213:30 pmRNSHolding(s) in Company
1st Apr 20217:00 amRNSTotal Voting Rights
22nd Mar 20217:00 amRNSInvestor Presentation
18th Mar 20211:57 pmRNSResults of Placing and Subscription
18th Mar 20217:00 amRNSProposed Placing and Subscription
1st Mar 20217:00 amRNSSaori Trial Update
3rd Feb 20214:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20214:36 pmRNSPrice Monitoring Extension
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:36 pmRNSPrice Monitoring Extension
25th Jan 20217:00 amRNSTrading Statement
11th Jan 20217:00 amRNSNotice of Trading Statement/Investor Presentation
5th Jan 20213:37 pmRNSBrazil approves PHC279 to Control Soybean Rust
11th Dec 20207:00 amRNSInvestor Presentation
9th Nov 20207:00 amRNSPlant Health Care and Wilbur-Ellis sign Agreement
7th Oct 20207:00 amRNSGrant of Options
6th Oct 20207:00 amRNSNew US PREtec Patents Issued
2nd Oct 20205:48 pmRNSSignificant Shareholder
25th Sep 20207:00 amRNSInvestor Presentation
23rd Sep 20207:00 amRNSInvestor Presentation
15th Sep 20207:00 amRNSInterim Report 30 June 2020
29th Jul 20207:00 amRNSTrading Statement
26th Jun 20204:41 pmRNSSecond Price Monitoring Extn
26th Jun 20204:36 pmRNSPrice Monitoring Extension
25th Jun 20207:00 amRNSGrant of Options
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
16th Jun 20207:00 amRNSPHC398 Approved by US EPA: PHC279 submitted to EPA
9th Jun 20207:00 amRNSGrant of options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.